INTRODUCTION
Cystic fibrosis (CF) is a lethal inherited disorder caused by somatic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in humans, affecting about 1 in 2500 live births. 1 Pathobiological symptoms of CF include mucosal obstruction of exocrine glands and pulmonary inflammation. 2 Chronic neutrophilic inflammation and pulmonary infections are among the chief contributors to morbidity and mortality in CF. 3 Patients with CF have increased levels of proinflammatory cytokines in the airways that include tumor necrosis factor-a, interleukin (IL)-1, IL-6 and IL-8, and reduced levels of antiinflammatory cytokines such as IL-10. 4 The success of gene therapy for CF airway disease is dependent on the efficient delivery and expression of the CFTR gene 5 in the cells of the respiratory epithelium. [6] [7] [8] Virus (that is, adenovirus (Ad), lentivirus and adeno-associated virus) vector-based gene transfer has been developed to correct the underlying Cl-secretion defect in the CF airway epithelium. 9, 10 Cellular and humoral immune responses to viral antigens, and the epitopes on the expressed proteins have been shown to be barriers to efficient airway gene transfer. 11, 12 Successful gene therapy regimens using virus-based vectors may also require the elimination of the antivector capsid immune responses. [13] [14] [15] It is likely that two sets of antigens induce a host immune response, the viral antigens associated with the virus vector and the non-tolerated antigens of the newly expressed proteins.
Regulatory T cells (T reg ) reduce pulmonary inflammation and lung injury in animal models of Pneumocystis pneumonia. 16 Activated CD4 þ CD25 þ FOXP3 þ T reg cells also suppress allergic airway inflammation. 17 We are particularly interested in the posttranslational modification of FOXP3 as a mechanism to regulate the activity of T reg cells. 18, 19 Acetylation of FOXP3 has been shown to increase the stability of the FOXP3 proteins. [19] [20] [21] Previously valproic acid (VPA), an HDAC inhibitor and a clinically safe compound, was shown to enhance the function of T reg cells to suppress effector cells. 22 Here we report a strategy that utilizes VPA to improve virus vector-based gene transfer in the CF mouse lung. VPA treatment increased T reg activity and reduced inflammation in the CF mouse lung, as demonstrated by the reduction of the number of neutrophils. Furthermore, following VPA treatment, we observed an increase in Ad vector-mediated gene expression. This study suggests that HDAC inhibitors may be developed and used as immune modulators to improve lung gene therapy.
RESULTS

Increased number of T reg cells in the bronchoalveolar lavage (BAL) fluid of CF mice
A CFTR knockout mouse model 23 has been used extensively to study CF-related disease and explore therapies. In our experiments to examine the role of T reg cells in the CF mouse lung, we compared the number of T reg cells in both CF and wild-type (WT) age-matched mice. Splenocytes as well as cells isolated from the BAL fluid were harvested from CF and WT mice and analyzed for the presence of T reg cells by fluorescence-activated cell sorting (FACS). No difference was observed in the frequency of spleenderived T reg cells between CF and WT mice. However, we did observe a higher percentage of T reg in the BAL fluid of CF mice when compared with the WT mice (7.7% ± 2.6 vs 0% ± 0, Figure 1b ), a likely consequence of the preexisting inflammatory status of the CF mouse lung. Compared with WT mice, CF mice had an increased number of Ly6G þ neutrophils (Figure 1c ), which are myeloid cells shown to contribute to the innate immune defense against microbial pathogens. 24 HDACi enhances Ad-mediated transgene expression in lung We first investigated if VPA could enhance Ad vector-mediated LacZ expression in mouse lung. CF mice were treated intraperitoneally with either low dose (1.33 mg) or high dose (2.67 mg) of VPA once daily for 4 days. On day 2, the mice were also given intranasally 5 Â 10 10 particles of Ad.LacZ vector in 50 ml. Expression of LacZ was assessed on day 5.
As expected, no transgene expression was observed in the lung of naïve mice. LacZ-expressing cells were present in the lung of animals that were given the Ad.LacZ vector intranasally. Treatment with the high dose of VPA resulted in a significant increase of LacZ expression in mouse airway when compared with the Ad.LacZ vector only-treated group (Figure 2e ). No improvement was observed in the level of LacZ expression in the lung of mice treated with the low dose of VPA (Figure 2e ).
VPA reduces inflammation in the lung of CF mice
In CF mice treated with either low or high dose of VPA, there was a considerable reduction in the neutrophil population but not in T reg cell numbers (data not shown). To understand if the T reg activity was changed by the VPA treatment, CD4 þ CD25 high T reg cells were isolated from the spleen and studied for their ability to suppress the proliferation of carboxyfluorescein diacetate succinimidyl ester-labeled primary CD4 þ CD25 À CD45RB high T cells (representing effector T cells (T eff )). Treatment with VPA dose-dependently increased T reg activity in the BAL fluid of CF mice that received the Ad.LacZ vector and less T eff cells underwent proliferation ( Figure 2f ).
We then studied the effect of VPA on CFTR gene transfer. Independent of the Ad.CFTR vector, VPA treatment only slightly increased the percentage of T reg cells in the BAL fluid of CF mice (Figure 3a) . The difference, however, was not statistically significant due to the significant variation between samples. Treatment with the Ad.CFTR vector alone did not appear to have an effect on the frequency of T reg cells in the BAL fluid. In contrast, VPA treatment or Ad.CFTR vector delivery led to a reduction in the frequency of neutrophils (Ly6G þ ) in the BAL fluid, suggesting less inflammation in these mice. VPA treatment combined with the Ad.CFTR vector delivery had an additive significant effect on the reduction of neutrophils compared to the naïve group (Po0.05) (Figure 3b ). To rule out a possible toxic effect of VPA on neutrophils, we also examined the population of splenocytes from each experimental group. VPA treatment did not significantly affect the frequency of neutrophils and T reg frequency in spleen ( Figure 3 ). Our data suggest that VPA treatment reduced BAL fluid neutrophil number by indirectly limiting inflammation and not by directly inducing cytotoxicity towards this population.
Although the frequency of T reg cells was not changed (Figure 3a) , we investigated whether the T reg activity was affected by either the VPA or the Ad.CFTR vector treatment. We examined T reg cells for their ability to suppress T eff cells as described above. T eff and T reg cells were mixed at a ratio of 2:1. The percentage of proliferative T eff cells was reduced from 75.4 (in the absence of T reg cells) to 57 by the addition of T reg cells from naïve CF mice (Figure 4 ). In the presence of VPA-treated T reg cells, the population of proliferating T eff cells was further reduced to 48.1%, indicating an enhanced T reg activity in CF mice following VPA treatment ( Figure 4 ). Interestingly, Ad.CFTR vector treatment had little effect on T reg activity, and the effect of the VPA and Ad.CFTR combination treatment was similar to the VPA-only treatment ( Figure 4 ). These data are consistent with the previously reported pro-T reg activity of VPA. 22 We expect that the CFTR expression in lung epithelial cells by the Ad.CFTR vector would limit inflammation by restoring CFTR activity and not by increasing T reg activity. We speculate that by invoking two mechanisms the Ad.CFTR and VPA combination treatment may lead to lower inflammation, as seen by the lower frequency of neutrophils in BAL fluid (Figure 3 ).
DISCUSSION
VPA has been shown to inhibit HDAC activity and affect the acetylation of histones and as such is expected to modulate gene transcription by promoting DNA decondensation. 18, 25 Previous studies have demonstrated that HDAC inhibitors alone are insufficient to broadly modify gene expression. In a microarray study, the pan-HDAC inhibitor trichostatin was shown to influence (equal distribution of up-or downregulation) the transcription of B2% genes in T cells. 26 In another study using the pan-HDAC inhibitor LAQ824, the Toll-like receptor 4-dependent activation of macrophages was examined and only 5% of genes were found to be either up-or downregulated. 27 Fan et al. 28 reported that treatment with VPA resulted in increased expression of exogenous genes in cells transduced with various viral-based gene transfer vectors, including Ad, adenoassociated virus and herpesvirus vectors. Recently, the effect of VPA on Ad vector-mediated transduction was reported. VPA concentrations as low as 1 mM increased the Ad-vector transduction of glioma cells by seven-fold. 29 Although the pleiotropic effects of VPA may also contribute to the enhanced gene transfer in the airway observed in our study, the focus of our studies was the immunosuppressive effect of VPA through the regulation of T reg activity (Figure 2 ).
Inflammatory responses that arise following virus vectormediated gene therapy in CF airway may involve cytotoxic T cells, 13 T helper cells 30 and dendritic cells. 31 CD4 þ CD25 þ FOXP3 þ T reg cells suppress the function of all these immune cells. 32 Although T reg abnormalities have been reported in CF patients, 33 the role of T reg cells in CF disease pathogenesis remains unclear.
We examined CD4 þ CD25 þ FOXP3 þ T reg cells isolated from CF mice and observed an increase in the number of both T reg cells and neutrophils in BAL fluid. Our observations are consistent with previous reports of higher frequency of T reg cells at sites of ongoing chronic inflammation in lung 34 and the pathological influx of neutrophils in the airways of CF due to the loss of the CFTR function. 35 In some CF patients, signs of inflammation, such as neutrophil accumulation, high concentration of IL-8 and abundance of free protease, are often observed in the airways even in the absence of an infection. 36 We hypothesize that the HDAC inhibitor VPA functions as an immune suppressor by promoting FOXP3 acetylation as previously shown 18 and enhancing the function of T reg cells, as demonstrated in Figures 2f and 4 .
FOXP3 has an essential role in the development and function of natural and induced T reg cells and as such represents a key target to modulate T reg functions. 18, 37 Acetylation of FOXP3 is linked to the stability of FOXP3 21, 38 that can be regulated by acetyltransferases (that is, p300 and TIP60) and deacetylases (that is, HDAC7, HDAC9 and SIRT1). 20, 37, 39 Recent studies suggest that in vivo treatment with VPA increases the number and function of CD4 þ CD25 þ FOXP3 þ cells and reduces disease severity in the collagen-induced arthritis-animal model. 22 In our study CF mice were characterized by highly elevated levels of T reg cells in the BAL fluid compared with WT mice (Figure 1b) . Although VPA may further increase the frequency of T reg cells in CF mice, we propose that the ability of VPA to enhance T reg suppressive function is more critical and may instantly induce the pre-localized T reg cells.
Unexpectedly, we found that treatment with Ad vector reduced T reg activity in CF mice. As shown in Figure 2f , mice treated with only Ad.LacZ had much lower T reg activity than naïve mice. It is unclear whether the induced inactivation of T reg function by Ad.LacZ vector is related to the influence of the virus vector on the host immune system. Treatment with VPA prior to Ad.LacZ gene transfer restored T reg activity. We found that VPA treatment decreases neutrophil infiltration in the lung of CF mice (Figure 3b ). Co-treatment of VPA with the Ad.CFTR vector further reduced the number of neutrophils in the BAL fluid of CF mice.
The capability of CD4 þ CD25 þ Foxp3 þ T reg cells to reduce neutrophil survival and limit inflammatory response has been reported in several models. 40, 41 In a lipopolysaccharide-induced lung injury model, alveolar infiltration of both T reg cells and neutrophils was observed after acute lung injury, and the transfer of T reg cells to injured mice enhanced the clearance of neutrophils from BAL fluid. 41 Our data suggest that by inducing the activity of T reg cells, VPA appears to reduce neutrophils in the lung.
The clinical utility of Ad-based vectors for lung-gene therapy is severely limited by their immunogenicity and the low transduction efficiency of airway epithelial cells. 42 Compared with Adbased vectors, adeno-associated virus-based vectors are less inflammatory and thus favorable for repeat administration and long-term transgene expression. Furthermore, several adenoassociated virus serotypes exist with improved targeting and transduction of airway epithelial cells. 43, 44 Here, we demonstrate the use of the immune-suppressive HDAC inhibitor VPA to enhance transgene expression. In summary, VPA may complement the effectiveness of CFTR gene transfer by inducing T reg activity in vivo. Our studies support further evaluation of VPA as a potential complimentary therapeutic to diminish inflammation in CF airway. Other HDAC inhibitors (for example, vorinostat and romidepsin 45 ) that have been approved for clinical use can also be explored for their activity to facilitate virus vector-based gene transfer.
MATERIALS AND METHODS
Animal studies
Studies utilizing mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Ad-based vector at a dose of 5 Â 10 10 particles per mouse was delivered in 50 ml of phosphate-buffered saline (PBS) intranasally as described previously. 46 For the VPA plus the Ad.LacZ vector Figure 3 . In vivo effect of VPA. BAL fluid or spleen cells from mice subjected to different treatments as noted were collected for FACS analysis. Frequency of (a) T reg cells and (b) neutrophils was analyzed using FACS. *Po0.05, t-test. group, mice were treated daily with either 1.33 mg (low-dose group) or 2.67 mg (high-dose group) delivered intraperitoneally for 4 consecutive days. The Ad.LacZ vector was dosed on the second day after VPA injection. On the fifth day, BAL fluid and lung tissue were collected. For the VPA plus the Ad.CFTR vector group, mice were first treated with 2.67 mg VPA or PBS by intraperitoneal injection on the day before as well as on the day of virus vector administration. Mice were further treated with 8 mg VPA three times over the period of 1 week after receiving the Ad.CFTR vector. Spleen cells and BAL fluid were collected for the analysis. PBS was used as the control treatment. Lungs from mice were inflated with 1:1 PBS/OCT (optimum cutting temperature) compound, prepared as 8 mm tissue sections and stained for LacZ expression. The slides were counterstained with Safranin O. 46 Flow cytometry Spleen cells and BAL fluid cells were collected and a single suspension of cells was incubated with 5% FCS containing PBS to block the Fc receptor. Cells were stained with anti CD4-FITC, CD25-PE (BD Pharmingen, San Diego, CA, USA) and anti-Ly6G (Biolegend, San Diego, CA, USA). After washing, cells were fixed and stained with anti Foxp3-APC (eBioscience) using Foxp3 staining buffer set (eBioscience, San Diego, CA, USA). Flow cytometry was performed by LSRII (BD) at the University of Pennsylvania Flow Cytometry Core Facility.
In vitro T reg suppression assay
CD4 þ T cells were isolated from the spleen of mice using the MACS CD4 þ T cell isolation kit II (Miltenyi, Auburn, CA, USA). CD4 þ CD25 À CD45RB high T eff cells and CD4 þ CD25 high T reg cells were isolated by FACS Aria II, yielding a purity of B97% for both type of cells. T eff cells were labeled with carboxyfluorescein diacetate succinimidyl ester (Invitrogen, Carlsbad, CA, USA), stimulated with anti-CD3/CD28 beads (Invitrogen), and co-cultured with different ratio of T reg cells. After 3 days of co-culture in RPMI supplemented with 10% fetal bovine serum, 1 Â non-essential amino acids (Invitrogen), 2 mM sodium pyruvate (Invitrogen) and 50 mM b-mercaptoethanol (Sigma, St Louis, MO, USA), cells were harvested and in vitro proliferation of lymphocytes was analyzed by the FACSCanto Flow Cytometry.
